Skip to main content
Sign in Create a free account
Varsity Tutors
Sign in

Adverse Reactions - NAPLEX

  1. A 67-year-old male (weight 74 kg) presents with dizziness and near-syncope after starting a new medication. Current medications: tamsulosin 0.4 mg by mouth nightly (started 2 days ago), sildenafil 50 mg by mouth as needed (took a dose last night), lisinopril 10 mg by mouth daily, and hydrochlorothiazide 25 mg by mouth daily. Blood pressure in clinic is 88/56 mmHg; labs: serum creatinine 1.1 mg/dL, potassium 4.2 mEq/L; allergies: none; medical history: benign prostatic hyperplasia, erectile dysfunction, hypertension. What is the most likely adverse reaction in this patient?
    Answer: Orthostatic hypotension due to additive blood pressure–lowering effects of tamsulosin and sildenafil This question tests recognition of drug interaction-induced orthostatic hypotension. The patient's hypotension and near-syncope after combining tamsulosin (alpha-1 blocker) with sildenafil (PDE5 inhibitor) demonstrates additive vasodilation, as both cause peripheral vasodilation through different mechanisms. The correct answer (A) identifies this pharmacodynamic interaction. Option B incorrectly suggests hyperkalemia which doesn't cause these symptoms and isn't caused by this combination. Option C wrongly invokes serotonin syndrome which sildenafil doesn't cause. Option D incorrectly suggests bronchospasm from tamsulosin allergy which would present with respiratory symptoms. Alpha blockers and PDE5 inhibitors should be used cautiously together with dose separation (4-6 hours), starting with lowest doses, and counseling about orthostatic precautions. Consider alternative BPH treatments like 5-alpha reductase inhibitors in patients requiring PDE5 inhibitors.
  2. A 65-year-old man (77 kg) presents with new-onset wheezing and shortness of breath shortly after starting an eye drop for glaucoma. Medical history: asthma, open-angle glaucoma. Current medications: timolol ophthalmic 0.5% 1 drop in each eye twice daily (started 3 days ago), albuterol inhaler as needed, budesonide/formoterol inhaler twice daily. Labs: serum creatinine 0.9 mg/dL, alanine aminotransferase 16 units/L. Allergies: none. Which medication is causing these symptoms?
    Answer: Timolol ophthalmic causing bronchospasm from systemic beta-blockade This question tests the recognition of systemic adverse effects from topical ophthalmic medications, particularly beta-blockers in patients with respiratory conditions. The key patient-specific factor is the history of asthma combined with the recent initiation of timolol ophthalmic drops, a non-selective beta-blocker. Timolol is the best choice as the causative agent because it can be systemically absorbed, leading to beta-2 receptor blockade in the lungs and subsequent bronchospasm, which aligns with the new-onset wheezing and shortness of breath starting shortly after initiation. Albuterol is incorrect because paradoxical bronchospasm is a rare adverse effect, not the most common, and the symptoms began after timolol initiation, not albuterol use. Budesonide and formoterol are suboptimal choices as budesonide does not typically cause acute bronchospasm from steroid allergy, and formoterol is not associated with pulmonary edema within days of starting. A key clinical pearl is to monitor for systemic effects of ophthalmic beta-blockers in patients with contraindications like asthma, opting for alternatives such as prostaglandin analogs if possible. When evaluating adverse reactions, always consider the timeline of medication initiation relative to symptom onset to identify the most likely culprit.
  3. A 62-year-old woman (64 kg) presents with severe muscle weakness and arrhythmia after starting a diuretic 2 weeks ago. Medical history: hypertension. Current medications: hydrochlorothiazide 25 mg by mouth daily (started 2 weeks ago), amlodipine 5 mg by mouth daily. Labs: potassium 2.7 mEq/L (low), magnesium 1.4 mg/dL (low), serum creatinine 0.9 mg/dL, alanine aminotransferase 15 units/L. Allergies: none. What is the best management strategy for this adverse reaction?
    Answer: Recommend potassium and magnesium repletion and reassess diuretic therapy (dose reduction or alternative) with follow-up electrolytes This question tests the management of thiazide diuretic-induced electrolyte imbalances like hypokalemia and hypomagnesemia. The key patient-specific factor is the recent initiation of hydrochlorothiazide leading to muscle weakness and arrhythmia with low potassium (2.7 mEq/L) and magnesium (1.4 mg/dL). Option A is the best choice because repleting potassium and magnesium, reassessing diuretic therapy (e.g., dose reduction or switch), and follow-up monitoring corrects the imbalances and prevents complications like arrhythmias. Option B is incorrect as restricting potassium risks worsening hypokalemia, option C is wrong because amlodipine does not cause these electrolytes changes, and option D is suboptimal as sodium bicarbonate does not address hypomagnesemia. A clinical pearl is that thiazides promote renal potassium and magnesium loss, increasing arrhythmia risk in hypertensive patients. A decision framework for diuretic side effects involves checking electrolytes within 2-4 weeks of initiation, repleting as needed, and considering potassium-sparing alternatives if recurrent.
  4. A 56-year-old woman (70 kg) comes to urgent care for facial swelling and difficulty breathing 30 minutes after taking her first dose of amoxicillin-clavulanate 875/125 mg by mouth for sinusitis. Medical history: asthma, allergic rhinitis. Current medications: albuterol inhaler as needed, fluticasone nasal spray daily, amoxicillin-clavulanate 875/125 mg by mouth twice daily (first dose taken). Vitals: blood pressure 92/58 mmHg, heart rate 118 bpm. Labs: serum creatinine 0.8 mg/dL, alanine aminotransferase 18 units/L. Allergies: none documented. What is the best management strategy for this adverse reaction?
    Answer: Administer intramuscular epinephrine promptly and ensure emergency care; document a beta-lactam allergy and discontinue amoxicillin-clavulanate This question tests the identification and acute management of anaphylaxis as an adverse reaction to beta-lactam antibiotics like amoxicillin-clavulanate. The key patient-specific factor is the rapid onset of facial swelling, difficulty breathing, hypotension (92/58 mmHg), and tachycardia (118 bpm) shortly after the first dose, indicative of a severe allergic reaction in a patient with asthma history increasing risk. Option A is the best choice because it involves prompt administration of intramuscular epinephrine for anaphylaxis, ensures emergency care, documents the allergy, and discontinues the offending antibiotic to prevent further exposure. Option B is incorrect as diphenhydramine alone is insufficient for anaphylaxis and continuing the antibiotic risks recurrence, while option C is suboptimal because cephalosporins like cephalexin can cross-react in beta-lactam allergies. Option D is wrong as this presentation aligns with allergy rather than asthma exacerbation, and albuterol alone does not address the systemic reaction. A transferable clinical pearl is that anaphylaxis requires immediate epinephrine as first-line treatment, with adjunctive antihistamines and steroids for support. In decision-making for drug allergies, always assess symptom timing and severity to differentiate IgE-mediated reactions from other adverse effects, and update allergy records to guide future prescribing.
  5. A 45-year-old female (weight 60 kg) treated for bipolar disorder reports excessive thirst, frequent urination, and worsening hand tremor. Current medications: lithium carbonate 300 mg by mouth three times daily (stable dose), ibuprofen 600 mg by mouth three times daily started 1 week ago for dental pain, and quetiapine 200 mg by mouth nightly. Labs: lithium concentration 1.8 mEq/L (high; typical maintenance 0.6–1.0 mEq/L), serum creatinine 1.6 mg/dL (baseline 0.9 mg/dL), sodium 147 mEq/L (high); allergies: none; medical history: bipolar disorder. Which action should the pharmacist take to address this adverse reaction?
    Answer: Hold lithium and advise urgent evaluation for lithium toxicity; recommend avoiding nonsteroidal anti-inflammatory drugs and notify the prescriber to use an alternative analgesic and recheck lithium level and renal function This question tests management of lithium toxicity from drug interactions. The patient's polyuria, polydipsia, tremor, elevated lithium level, and increased creatinine after starting ibuprofen indicates lithium toxicity, as NSAIDs reduce renal lithium clearance by inhibiting prostaglandin synthesis. The correct answer (B) appropriately holds lithium, recommends urgent evaluation, avoids NSAIDs, and ensures proper monitoring. Option A dangerously continues both drugs and restricts fluids which could worsen toxicity. Option C incorrectly blames quetiapine which doesn't significantly affect lithium levels. Option D shows dangerous misunderstanding by increasing lithium dose. NSAIDs can increase lithium levels by 20-60% within days; safer alternatives include acetaminophen or aspirin (with caution). When NSAIDs are necessary, reduce lithium dose prophylactically by 20-25% and monitor levels within 4-5 days.
  6. A 73-year-old woman (55 kg) presents with confusion and unsteady gait 4 days after starting ciprofloxacin for a urinary tract infection. Medical history: chronic kidney disease stage 3, seizure disorder (remote). Current medications: ciprofloxacin 500 mg by mouth twice daily (started 4 days ago), theophylline 300 mg by mouth twice daily for COPD, levetiracetam 500 mg by mouth twice daily. Labs: serum creatinine 1.6 mg/dL, theophylline level 24 mcg/mL (high; typical 10–20), alanine aminotransferase 25 units/L. Allergies: none. What is the most likely adverse reaction in this patient?
    Answer: Theophylline toxicity due to ciprofloxacin increasing theophylline concentrations This question tests the recognition of theophylline toxicity from CYP1A2 inhibition by ciprofloxacin. The key patient-specific factor is the onset of confusion and unsteady gait after starting ciprofloxacin in a patient on theophylline, with elevated theophylline level (24 mcg/mL) due to reduced clearance in chronic kidney disease. Option A is the best choice because it correctly identifies the interaction causing toxicity, requiring ciprofloxacin discontinuation or theophylline adjustment. Option B is incorrect as ciprofloxacin does not cause opioid overdose, option C is wrong because levetiracetam does not induce serotonin syndrome, and option D is suboptimal as ciprofloxacin does not trigger adrenal crisis. A clinical pearl is that fluoroquinolones like ciprofloxacin can increase theophylline levels by 25-100%, risking seizures or arrhythmias in vulnerable patients. A decision framework for theophylline management involves monitoring levels (target 8-15 mcg/mL for COPD), adjusting for inhibitors, and considering alternatives like inhaled therapies in high-risk cases.
  7. A 63-year-old man (90 kg) presents with diffuse muscle pain and dark urine that began 1 week after his cardiologist added a new medication. Medical history: hyperlipidemia, coronary artery disease, type 2 diabetes. Current medications: simvastatin 40 mg by mouth nightly, metformin 1000 mg by mouth twice daily, aspirin 81 mg by mouth daily, and clarithromycin 500 mg by mouth twice daily started 7 days ago for pneumonia. Labs: creatine kinase 3,800 units/L (high), serum creatinine 1.9 mg/dL (baseline 1.0), alanine aminotransferase 45 units/L. Allergies: none. Which medication is causing these symptoms?
    Answer: Clarithromycin interacting with simvastatin leading to statin-associated myopathy/rhabdomyolysis This question tests the recognition of drug-drug interactions causing statin-associated muscle injury, specifically rhabdomyolysis. The key patient-specific factor is the recent addition of clarithromycin, a strong CYP3A4 inhibitor, to simvastatin (a CYP3A4 substrate), leading to elevated simvastatin levels and symptoms of muscle pain, dark urine, elevated CK (3,800 units/L), and acute kidney injury. Option C is the best choice because it correctly identifies the clarithromycin-simvastatin interaction as the cause of statin myopathy/rhabdomyolysis, which requires immediate discontinuation and supportive care. Option A is incorrect as metformin does not cause myopathy, option B is wrong because aspirin is not associated with these symptoms, and option D is suboptimal as simvastatin rarely causes cough or angioedema. A clinical pearl is that macrolides like clarithromycin can increase statin exposure multifold, raising rhabdomyolysis risk, especially at higher statin doses. In managing statin interactions, always check for CYP inhibitors and consider switching to non-interacting statins like pravastatin or rosuvastatin.
  8. A 49-year-old man (80 kg) taking lithium for bipolar disorder presents with worsening tremor, nausea, and slurred speech after starting a new blood pressure medication last week. Current medications: lithium carbonate 900 mg/day by mouth in divided doses, hydrochlorothiazide 25 mg by mouth daily started 7 days ago, quetiapine 200 mg by mouth at bedtime. Labs: lithium level 1.9 mEq/L (high; typical maintenance 0.6–1.2), serum creatinine 1.3 mg/dL (baseline 1.0), sodium 134 mEq/L. Allergies: none. Which medication is causing these symptoms?
    Answer: Hydrochlorothiazide increasing lithium concentrations leading to lithium toxicity This question tests the recognition of lithium toxicity from drug interactions affecting renal clearance. The key patient-specific factor is the recent addition of hydrochlorothiazide, which reduces lithium excretion leading to elevated levels (1.9 mEq/L) and symptoms like tremor, nausea, and slurred speech. Option B is the best choice because it identifies hydrochlorothiazide as the cause of lithium toxicity, requiring discontinuation or dose adjustment of lithium with monitoring. Option A is incorrect as quetiapine does not inhibit CYP3A4 or elevate lithium, option C is wrong because lithium does not cause anaphylaxis, and option D is suboptimal as hydrochlorothiazide does not induce serotonin syndrome. A clinical pearl is that thiazides can increase lithium levels by 25-40% via sodium depletion and reduced clearance. A decision framework for lithium therapy involves monitoring levels (target 0.6-1.2 mEq/L) with any diuretic or NSAID addition, holding doses if toxic, and ensuring hydration to prevent recurrence.
  9. A 64-year-old man (80 kg) presents with new gynecomastia and breast tenderness after several months on a heart failure regimen. Medical history: heart failure with reduced ejection fraction, hypertension. Current medications: spironolactone 25 mg by mouth daily, lisinopril 20 mg by mouth daily, metoprolol succinate 100 mg by mouth daily, furosemide 20 mg by mouth daily. Labs: potassium 4.8 mEq/L, serum creatinine 1.1 mg/dL, alanine aminotransferase 17 units/L. Allergies: none. What is the best management strategy for this adverse reaction?
    Answer: Switch spironolactone to eplerenone and monitor potassium and renal function This question tests the management of spironolactone-induced gynecomastia in heart failure patients. The key patient-specific factor is the development of gynecomastia and breast tenderness after months on spironolactone, due to its anti-androgenic effects in a male patient with heart failure. Option B is the best choice because switching to eplerenone, a selective aldosterone antagonist, maintains heart failure benefits while reducing endocrine side effects like gynecomastia, with monitoring for hyperkalemia. Option A is incorrect as ACE inhibitors like lisinopril do not cause gynecomastia, and option C is wrong because adding testosterone is not standard and may have risks. Option D is suboptimal as increasing spironolactone would worsen symptoms. A clinical pearl is that spironolactone causes gynecomastia in up to 10% of men due to estrogenic activity, whereas eplerenone has lower incidence. In heart failure therapy, if endocrine effects occur, switch to eplerenone while ensuring potassium and renal monitoring to balance efficacy and tolerability.
  10. A 76-year-old female (weight 54 kg) is seen for nausea, decreased appetite, and yellow-green vision changes for 1 week. Current medications: digoxin 0.25 mg by mouth daily, furosemide 40 mg by mouth daily, and metoprolol succinate 100 mg by mouth daily. Labs: serum creatinine 1.8 mg/dL (baseline 1.1 mg/dL), potassium 3.1 mEq/L (low), digoxin concentration 2.6 ng/mL (high; typical goal 0.5–0.9 ng/mL for heart failure); allergies: none; medical history: heart failure with reduced ejection fraction, atrial fibrillation, chronic kidney disease. Which monitoring parameter should be assessed to prevent further adverse reactions?
    Answer: Serum potassium and renal function (serum creatinine) with reassessment of digoxin concentration after dose adjustment This question tests monitoring parameters for digoxin toxicity prevention. The patient presents with classic digoxin toxicity symptoms (nausea, anorexia, visual disturbances) with elevated level, worsening renal function, and hypokalemia - all factors that increase digoxin toxicity risk. The correct answer (A) identifies the need to monitor potassium (as hypokalemia increases digoxin binding to Na-K-ATPase) and renal function (as digoxin is renally eliminated). Option B incorrectly suggests HbA1c monitoring which is unrelated to digoxin toxicity. Option C suggests INR monitoring but digoxin doesn't significantly interact with warfarin. Option D incorrectly suggests CK monitoring as digoxin doesn't cause myopathy. Key principle: digoxin has a narrow therapeutic index requiring monitoring of levels, renal function, and potassium, with dose adjustments for declining kidney function and correction of hypokalemia to prevent toxicity.
  11. A 35-year-old female (weight 68 kg) presents to the emergency department with facial swelling, lip tingling, and diffuse urticaria 30 minutes after taking her first dose of amoxicillin-clavulanate 875 mg/125 mg by mouth for sinusitis. Current medications: sertraline 50 mg by mouth daily and an ethinyl estradiol/levonorgestrel oral contraceptive daily. Vitals are stable; labs: serum creatinine 0.8 mg/dL, liver function tests within normal limits; allergies: none previously reported; medical history: depression. What is the best management strategy for this adverse reaction?
    Answer: Stop amoxicillin-clavulanate immediately, treat as an acute allergic reaction (including appropriate antihistamine and escalation if symptoms worsen), and document a penicillin allergy with prescriber notification for alternative therapy This question tests recognition and management of acute penicillin allergy. The patient's facial swelling, lip tingling, and urticaria within 30 minutes of first amoxicillin-clavulanate dose indicates IgE-mediated (Type I) hypersensitivity reaction with potential for anaphylaxis progression. The correct answer (B) appropriately stops the offending drug immediately, treats the allergic reaction, documents the allergy, and ensures alternative therapy. Option A is dangerous as continuing the antibiotic could lead to anaphylaxis. Option C incorrectly blames sertraline which doesn't cause acute urticaria. Option D inappropriately focuses on the oral contraceptive which isn't implicated. Penicillin allergies must be taken seriously with immediate discontinuation, appropriate treatment based on severity, and clear documentation to prevent future exposures. Cross-reactivity with cephalosporins is approximately 1-2% with current generation agents.
  12. A 52-year-old male (weight 86 kg) with chronic back pain reports constipation with no bowel movement for 5 days, abdominal discomfort, and straining. Current medications: oxycodone immediate-release 10 mg by mouth every 6 hours as needed (using 4 doses/day for 3 months), gabapentin 300 mg by mouth three times daily, and omeprazole 20 mg by mouth daily. Labs: serum creatinine 1.0 mg/dL, liver function tests within normal limits; allergies: none; medical history: chronic pain, gastroesophageal reflux disease. What is the best management strategy for this adverse reaction?
    Answer: Initiate a scheduled stimulant laxative plus stool softener (e.g., senna with docusate) and counsel on hydration/fiber; consider adding an osmotic agent if inadequate response This question tests management of opioid-induced constipation (OIC), a predictable adverse effect. The patient's constipation after 3 months of regular oxycodone use is classic OIC, occurring in up to 95% of chronic opioid users due to mu-receptor activation in the GI tract. The correct answer (B) appropriately recommends scheduled bowel regimen with stimulant laxative (for motility) plus stool softener, with potential osmotic agent escalation. Option A incorrectly blames gabapentin which rarely causes severe constipation. Option C wrongly implicates omeprazole and misunderstands the mechanism. Option D dangerously recommends loperamide (an anti-diarrheal) which would worsen constipation. Key principle: OIC requires prophylactic bowel regimens starting with opioid initiation, as tolerance doesn't develop to GI effects unlike analgesia, using scheduled rather than PRN laxatives.
  13. A 58-year-old man (92 kg) presents with severe constipation and abdominal discomfort for 1 month. Medical history: chronic pain, hypertension. Current medications: oxycodone extended-release 20 mg by mouth twice daily (chronic), oxycodone immediate-release 5 mg by mouth every 6 hours as needed, amlodipine 10 mg by mouth daily. Labs: serum creatinine 1.0 mg/dL, alanine aminotransferase 21 units/L. Allergies: none. What is the best management strategy for this adverse reaction?
    Answer: Start a stimulant laxative plus stool softener (or an osmotic laxative) as a scheduled bowel regimen while continuing opioid therapy This question tests the prevention and management of opioid-induced constipation in chronic pain patients. The key patient-specific factor is the patient's long-term use of oxycodone, leading to severe constipation and abdominal discomfort due to mu-opioid receptor effects on gut motility. Option A is the best choice because initiating a scheduled bowel regimen with stimulants like senna plus stool softeners or osmotics like polyethylene glycol effectively prevents and treats opioid constipation without altering pain control. Option B is incorrect as loperamide would worsen constipation, option C is wrong because amlodipine rarely causes severe constipation, and option D is suboptimal as dietary iron is unrelated. A clinical pearl is that nearly all patients on chronic opioids develop constipation, requiring prophylactic laxatives rather than waiting for symptoms. A decision framework for opioid side effects involves starting bowel regimens at opioid initiation, escalating from stimulants to peripherally acting mu-opioid antagonists if refractory, while monitoring for dehydration or obstruction.
  14. A 45-year-old woman (65 kg) with major depressive disorder reports new restlessness, sweating, tremor, and diarrhea after a medication change 2 days ago. Current medications: sertraline 100 mg by mouth daily (stable for 6 months), linezolid 600 mg by mouth twice daily started 2 days ago for MRSA skin infection, and ondansetron 4 mg by mouth every 8 hours as needed. Vitals: temperature 38.6°C, heart rate 112 bpm. Labs: serum creatinine 0.9 mg/dL, alanine aminotransferase 20 units/L. Allergies: none. What is the most likely adverse reaction in this patient?
    Answer: Serotonin syndrome due to linezolid with sertraline This question tests the identification of serotonin syndrome from monoamine oxidase inhibitor (MAOI) interactions with serotonergic agents. The key patient-specific factor is the recent initiation of linezolid (a weak MAOI) in a patient on sertraline (an SSRI), leading to symptoms like restlessness, sweating, tremor, diarrhea, fever (38.6°C), and tachycardia (112 bpm). Option A is the best choice because it accurately diagnoses serotonin syndrome due to the linezolid-sertraline interaction, which requires discontinuation of offending agents and supportive care. Option B is incorrect as neuroleptic malignant syndrome is associated with antipsychotics, not ondansetron, and option C is wrong because acute dystonia is not typical of sertraline. Option D is suboptimal as Stevens-Johnson syndrome presents with skin lesions, not these autonomic symptoms. A clinical pearl is that linezolid's MAOI activity can precipitate serotonin syndrome with SSRIs, necessitating a washout period. A decision framework for suspected serotonin syndrome involves assessing the Hunter criteria (e.g., clonus, tremor) and promptly removing serotonergic drugs while providing benzodiazepines for symptom control.
  15. A 76-year-old man (70 kg) is brought in for confusion and lethargy. Medical history: chronic pain, insomnia, chronic kidney disease stage 4. Current medications: morphine immediate-release 15 mg by mouth every 4 hours as needed (using 5–6 doses/day), gabapentin 300 mg by mouth three times daily, temazepam 15 mg by mouth at bedtime. Labs: serum creatinine 2.9 mg/dL (high), alanine aminotransferase 18 units/L. Respiratory rate is 10 breaths/min. Allergies: none. Which action should the pharmacist take to address this adverse reaction?
    Answer: Recommend reducing/avoiding morphine in severe renal impairment and urgent evaluation for opioid toxicity; consider safer opioid alternatives and dose adjustments This question tests the management of opioid toxicity in renal impairment, focusing on morphine accumulation. The key patient-specific factor is the patient's chronic kidney disease stage 4 (creatinine 2.9 mg/dL) leading to reduced clearance of morphine's active metabolite (M6G), causing confusion, lethargy, and respiratory depression (10 breaths/min). Option A is the best choice because it recommends reducing or avoiding morphine in severe renal impairment, urgent evaluation for toxicity, and considering safer opioids like fentanyl or hydromorphone with dose adjustments. Option B is incorrect as increasing temazepam would worsen sedation, option C is wrong because diphenhydramine adds anticholinergic risks, and option D is suboptimal as pregabalin also requires renal adjustment and may not reverse effects. A clinical pearl is that morphine metabolites accumulate in renal failure, prolonging sedation and respiratory depression. A decision framework for pain management in CKD involves selecting opioids with minimal renal excretion, starting low and slow, and monitoring for CNS effects with naloxone readiness for overdose.
  16. A 52-year-old man (95 kg) with type 2 diabetes reports shakiness, sweating, and confusion that improved after drinking juice. He recently started a new antibiotic yesterday. Current medications: glyburide 10 mg by mouth daily, metformin 1000 mg by mouth twice daily, trimethoprim-sulfamethoxazole DS 1 tablet by mouth twice daily (started yesterday). Labs: glucose 48 mg/dL (low), serum creatinine 1.1 mg/dL, alanine aminotransferase 19 units/L. Allergies: none. What is the most likely adverse reaction in this patient?
    Answer: Hypoglycemia due to an interaction increasing sulfonylurea effect This question tests the recognition of drug-induced hypoglycemia from sulfonylurea interactions. The key patient-specific factor is the recent initiation of trimethoprim-sulfamethoxazole (TMP-SMX), which inhibits CYP2C9 metabolism of glyburide, leading to enhanced sulfonylurea effects and symptomatic hypoglycemia (glucose 48 mg/dL). Option A is the best choice because it correctly identifies the interaction causing hypoglycemia, requiring TMP-SMX discontinuation or glyburide adjustment. Option B is incorrect as TMP-SMX does not cause hyperglycemia, and option C is wrong because metformin lactic acidosis is rare with normal renal function. Option D is suboptimal as glyburide does not cause diabetic ketoacidosis. A clinical pearl is that sulfonylureas like glyburide have higher hypoglycemia risk in the elderly or with CYP inhibitors like TMP-SMX. A decision framework for hypoglycemia involves checking for drug interactions, treating acutely with glucose, and adjusting therapy to prevent recurrence.
  17. A 61-year-old female (weight 70 kg) comes to the clinic for fatigue, nausea, and right upper quadrant discomfort. Current medications: isoniazid 300 mg by mouth daily started 2 months ago for latent tuberculosis infection, pyridoxine 25 mg by mouth daily, and acetaminophen 1000 mg by mouth three times daily for osteoarthritis. Labs: alanine aminotransferase 210 U/L (high; normal 7–56 U/L), aspartate aminotransferase 180 U/L (high; normal 10–40 U/L), total bilirubin 2.4 mg/dL (high); serum creatinine 0.8 mg/dL; allergies: none; medical history: osteoarthritis. Which medication is causing these symptoms?
    Answer: Isoniazid 300 mg by mouth daily This question tests recognition of isoniazid-induced hepatotoxicity. The patient's elevated transaminases (ALT>AST pattern), hyperbilirubinemia, and symptoms after 2 months of isoniazid therapy indicates drug-induced liver injury, a known adverse effect occurring in 1-2% of patients. The correct answer (B) identifies isoniazid as the cause. Option A incorrectly suggests pyridoxine which is given to prevent peripheral neuropathy and doesn't cause hepatotoxicity. Option C wrongly states acetaminophen at therapeutic doses always causes jaundice, when hepatotoxicity typically requires doses >4g/day or risk factors. Option D incorrectly suggests latent TB causes hepatitis when it's asymptomatic by definition. Isoniazid hepatotoxicity risk increases with age, alcohol use, and concurrent hepatotoxic drugs; monitoring includes baseline and periodic liver function tests with drug discontinuation for ALT >3x upper limit with symptoms or >5x without symptoms.
  18. A 70-year-old man (85 kg) on warfarin for atrial fibrillation presents for INR check after starting a new medication 6 days ago. Current medications: warfarin 5 mg by mouth daily (stable), amiodarone 200 mg by mouth daily started 6 days ago, levothyroxine 100 mcg by mouth daily. Labs: INR 5.6 (high; goal 2–3), hemoglobin 13.8 g/dL, serum creatinine 1.0 mg/dL, alanine aminotransferase 28 units/L. He reports mild gum bleeding when brushing teeth. Allergies: none. What is the best management strategy for this adverse reaction?
    Answer: Hold 1–2 warfarin doses and reduce the maintenance dose with close INR follow-up due to the amiodarone interaction This question tests the management of warfarin drug interactions, specifically with amiodarone causing supratherapeutic INR. The key patient-specific factor is the recent initiation of amiodarone, which inhibits warfarin metabolism via CYP2C9, leading to elevated INR (5.6) and minor bleeding in a stable patient. Option B is the best choice because holding 1-2 warfarin doses and reducing the maintenance dose with close INR monitoring safely addresses the interaction without overcorrecting. Option A is incorrect as the INR will not self-correct without adjustment, risking thrombosis or bleeding, and option C is wrong because stopping amiodarone abruptly could destabilize arrhythmia control, and clopidogrel is not a warfarin substitute. Option D is suboptimal as vitamin K is reserved for major bleeding or very high INRs, not routine use. A clinical pearl is that amiodarone can increase warfarin effects by 25-50%, often requiring dose reductions of 20-40%. A decision framework for warfarin interactions involves anticipating potency (e.g., amiodarone's delayed onset), holding doses if INR >4-5 without bleeding, and frequent monitoring post-change.
  19. A 55-year-old man (86 kg) with HIV presents with yellowing of the eyes and dark urine 1 month after starting a new antiretroviral regimen. Current medications: atazanavir 300 mg by mouth daily boosted with ritonavir 100 mg by mouth daily (started 1 month ago), tenofovir disoproxil fumarate/emtricitabine 300/200 mg by mouth daily. Labs: total bilirubin 4.2 mg/dL (high), alanine aminotransferase 28 units/L, aspartate aminotransferase 26 units/L, serum creatinine 1.0 mg/dL. Allergies: none. What is the most likely adverse reaction in this patient?
    Answer: Indirect hyperbilirubinemia due to atazanavir (benign jaundice with normal transaminases) This question tests the recognition of atazanavir-induced indirect hyperbilirubinemia as a benign adverse effect. The key patient-specific factor is the onset of scleral icterus and dark urine 1 month after starting atazanavir, with isolated elevated total bilirubin (4.2 mg/dL) but normal transaminases, due to UGT1A1 inhibition. Option A is the best choice because it identifies the benign, unconjugated hyperbilirubinemia from atazanavir, which does not require discontinuation unless symptomatic. Option B is incorrect as emtricitabine rarely causes liver failure, option C is wrong because ritonavir does not cause hemolytic anemia, and option D is suboptimal as tenofovir causes renal rather than hepatic toxicity. A clinical pearl is that atazanavir commonly causes asymptomatic jaundice in 5-10% of patients, resolving upon discontinuation but often tolerable. In antiretroviral management, monitor bilirubin at baseline and periodically, distinguishing benign elevations from hepatotoxicity by checking direct bilirubin and liver enzymes.
  20. A 66-year-old woman (58 kg) with osteoporosis presents with severe heartburn and pain when swallowing that began after starting a new medication 2 weeks ago. She reports taking the medication with a small sip of water right before lying down at bedtime. Current medications: alendronate 70 mg by mouth once weekly (started 2 weeks ago), calcium carbonate 500 mg by mouth twice daily, vitamin D3 1000 units by mouth daily. Labs: serum creatinine 0.9 mg/dL, alanine aminotransferase 14 units/L. Allergies: none. What counseling point is most important to prevent this adverse reaction?
    Answer: Take alendronate with a full glass of water and remain upright for at least 30 minutes after the dose This question tests counseling to prevent bisphosphonate-induced esophagitis. The key patient-specific factor is the patient's improper administration of alendronate (small sip of water before lying down), leading to esophageal irritation with heartburn and odynophagia. Option B is the best choice because taking alendronate with a full glass of water and remaining upright for 30 minutes minimizes esophageal contact and reduces injury risk. Option A is incorrect as food decreases absorption and lying down increases reflux, while option C is wrong because crushing alters the formulation and may worsen irritation. Option D is suboptimal as bedtime dosing with calcium impairs absorption and heightens esophagitis risk. A clinical pearl is that bisphosphonates like alendronate can cause erosive esophagitis if not taken correctly, especially in patients with GERD history. A decision framework for bisphosphonate counseling emphasizes proper technique: fasting, full water, upright posture, and waiting 30 minutes before eating to optimize safety and efficacy.

Start this quiz